drugset / Trial / NCT01240382

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

NCT01240382

Phase 3 Completed 332 enrolled Santen Pharmaceutical Co., Ltd.

Summary

To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6 times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate ophthalmic solution (0.1% HA) (one drop at a time, 6 times daily, 4 weeks topical administration), is at least non-inferior in the change in fluorescein staining score, and is superior in the change in Rose bengal score, in a multicenter, double-masked, parallel-group comparison study. Safety profile will likewise be compared.

Timeline

Start
Primary completion
2008-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Diquafosol tetrasodium Oligonucleotide (other) 3 % Topical
Comparator Sodium Hyaluronate Other / unclassified 0.1 % Topical

Indications